



U.S. FOOD & DRUG
ADMINISTRATION

Data Standards Program Action Plan

Draft Version: 3.2

Document Date: July 18, 2018

REVISION HISTORY

Version Number	Revision Date	Description of Change
1.0	February 21, 2013	Initial Document
1.1	July 29, 2013	Quarterly Update
1.2	October 23, 2013	Quarterly Update
1.3	February 5, 2014	Quarterly Update
1.4	May 30, 2014	Quarterly Update
1.5	October 2, 2014	Quarterly Update
1.6	January 21, 2015	Quarterly Update
1.7	April, 8 2015	Quarterly Update
1.8	July 8, 2015	Quarterly Update
2.0	October 14, 2015	Update to reflect Data Standards Strategy v2.0 and quarterly project update
2.1	February 3, 2016	Quarterly Update
2.2	May 25, 2016	Quarterly Update
2.3	August 31, 2016	Quarterly Update
2.4	November 18, 2016	Quarterly Update
2.5	March 15, 2017	Quarterly Update
2.6	June 29, 2017	Quarterly Update
2.7	December 26, 2017	Quarterly Update
3.0	February 28, 2018	Update to reflect Data Standards Strategy FY2018-2022 and quarterly project update
3.1	April 30, 2018	<ul style="list-style-type: none"> • Quarterly Update • Identification of Medicinal Product (IDMP) Project description was updated to reflect the use cases for the adoption of the IDMP standards (e.g., quality and safety of medicinal products).
3.2	July 18, 2018	Quarterly Update

Table of Contents

1	Introduction	1
2	Purpose	1
3	Program Goals and Initiatives.....	1
	Goal 1: Incorporate Data Standards to Support More Efficient, Science-Based Pre-Market Review of Medical Products	2
	Goal 2: Improve the postmarket risk management strategies and pharmacovigilance & surveillance of medical products by using data standards.....	5
	Goal 3: Implement common data standards to improve the quality and integrity of marketed medical products.....	7
	Goal 4: Promote innovation in the development and use of data standards	9
	Goal 5: Ensure effective communication and collaboration with stakeholders on data standards.	10
	Goal 6: Improve the management and usability of the volume of information through data standards	11
4	Upcoming Work	11
	Appendix A. Project Stage and Description	12
	Appendix B: Project to Goals/Objectives Mapping	15
	Appendix C: Glossary of Acronyms	16

Tables

Table 1. Pre-Market Projects	2
Table 2. Postmarket Projects.....	5
Table 3. Quality Projects.....	7
Table 4. Innovation Projects	9
Table 5. Communication Efforts.....	10
Table 6. Standard Development Project Stages.....	12
Table 7. Project Mapping	15

Figures

Figure 1. Data Standards Strategy Goals	1
Figure 2. Data Standards Development Framework.....	14

1 Introduction

The purpose of the [CBER-CDER Data Standards Strategy](#) is to reinforce the ongoing commitment to the development, implementation, and maintenance of a comprehensive data standards program that will facilitate the pre- and post-market regulatory review process so that safe and effective medical products are available to patients.

This action plan aligns to the CBER-CDER Data Standards Strategy and reflects progress in CBER and CDER towards the defined goals and objectives. Projects selected for this action plan have a scope that is primarily standards related, have started, and are resourced and funded.


2 Purpose

This Action Plan provides a quarterly update to internal and external stakeholders, with an overview and progress update of current data standards initiatives. The plan will continue to be updated quarterly to reflect progress of current projects, as well as, initiation of new projects.

3 Program Goals and Initiatives

The program goals are derived from the major areas of regulatory business activities. A detailed description of these major areas can be found in the CBER-CDER Data Standards Strategy. Projects in this section are organized by the goals outlined in the Strategy and shown below in **Figure 1**.

Figure 1. Data Standards Strategy Goals



For each project in this section, a project title, description, update, and project stage are provided. The project update reflects work done in the previous quarter (i.e., the February 2018 report highlights work from October to December 2017). The project stage lists the typical stages a project might address during work for the project and are generally conducted in sequence from left to right. Completed or planned stages are shown in gray, stage(s) in progress are in green and have an asterisk, and stage(s) that do not apply to a project are marked with diagonal stripes. The definitions of the project stage are defined in **Table 6**.

Goal 1: Incorporate Data Standards to Support More Efficient, Science-Based Pre-Market Review of Medical Products

Projects under Goal 1 generally address pre-market and submission standards. These include collaboration with stakeholders and Standards Development Organizations (SDO), and testing standards to be used for submission, content, and storage. Projects that highlight participation in initiatives focused on the harmonization of healthcare and clinical research data standards are highlighted here, and further addressed in Goal 4.

Table 1. Pre-Market Projects

Project Title and Description	Project Update	Project Stage						
<p>Evaluation and Testing of the SEND Standard for CBER The CBER project will evaluate and test the feasibility to support and require the Standard for Exchange of Nonclinical Data (SEND) standard to improve efficiency in the review process for nonclinical toxicology studies.</p>	<p>In FY18 Q2, the Clinical Data Interchange Standards Consortium (CDISC) created a sub-team who work with CBER identified subject matter experts (SMEs) to define the scope, create the charter and create the CDISC project request. The charter and CDISC project request are in draft stage. A review of the existing SEND Implementation Guide (SENDIG) will be performed to assess any CBER specific data needs.</p>	Req Definition	Alt Analysis*	Development	Testing	Adoption	Implementation	Policy

Project Title and Description	Project Update	Project Stage						
<p>Study Data Standards Testing This CBER-CDER project uses an established methodology to test new and version updates of study data standards to establish FDA support.</p>	<p>The following therapeutic area (TA) extensions were tested during the public comment period in FY18 Q3 and once verified after publication, the Study Data Technical Conformance Guide will be updated:</p> <ul style="list-style-type: none"> • Clostridium Difficile Associated Diarrhea (CDAD) <p>The following TA extensions were tested after CDISC final publication in FY18 Q3 and will be recommended to OpSC for adoption and addition to the Study Data Technical Conformance Guide:</p> <ul style="list-style-type: none"> • Duchenne Muscular Dystrophy <p>The following therapeutic areas will be added to the Study Data Technical Conformance Guide in October 2018:</p> <ul style="list-style-type: none"> • Prostate Cancer • Schizophrenia 	Req Definition	Alt Analysis	Development	Testing*	Adoption	Implementation	Policy
<p>BRIDG Architecture Review This CDER project is focused on the architectural review of the Biomedical Research Integrated Domain Group (BRIDG) model. The three project objectives are (1) Map BRIDG to Fast Healthcare Interoperability Resources (FHIR), (2) Formalize the modeling-by-reference approach, and (3) Develop a plan to reorganize BRIDG as a collection different “views” which show only the BRIDG classes relevant to a particular purpose or use case.</p>	<p>Q1: In FY18 Q1, the project collaborated with HL7 Biomedical Research and Regulation (BR&R) Workgroup re-architecture and usability subgroup to update FHIR ResearchStudy and ResearchSubject Resources. The mapping of BRIDG elements to FHIR resources continued during this quarter. FDA worked with BR&R to define areas of clinical research where FHIR resources could be leveraged. Lastly, BR&R identified an initial list of BRIDG model re-architecture changes.</p> <p>Q2: No updates this quarter</p> <p>Q3: No updates this quarter</p>	Req Definition	Alt Analysis	Development*	Testing	Adoption	Implementation	Policy

Project Title and Description	Project Update	Project Stage						
<p>eCTD v4.0 Project This CBER-CDER project focus is the development, testing, adoption, and implementation of the next major version of the electronic Common Technical Document. (eCTD) version 4 which includes two-way communication. FDA currently uses eCTD version 3.2.2.</p>	<p>The FDA is finalizing the initial draft eCTD v4.0 Technical Conformance Guide. The International Council for Harmonisation (ICH) M8 group completed an update the ICH eCTD v4.0 Implementation Package during the ICH June 2018 meeting. The updated implementation package (v1.3) should be posted on the ICH eCTD v4.0 webpage in August 2018.</p>	Req Definition	Alt Analysis	Development	Testing	Adoption*	Implementation	Policy
<p>Source Data Capture from EHRs: Using Standardized Clinical Research Data This CDER project is working to demonstrate an approach to collecting data for clinical trials that populates an electronic data capture (EDC) system directly from an electronic health record (EHR) system and document improvements to efficiency and accuracy compared to traditional methodologies.</p>	<p>Q1: In FY18 Q1, the project continued discussions with project data partners, developed metrics for assessing benefits of using an EHR-to-EDC solution for clinical research, and began planning approach to evaluating an EHR-to-EDC solution. Q2: No updates this quarter Q3: No updates this quarter</p>	Req Definition	Alt Analysis*	Development	Testing	Adoption	Implementation	Policy
<p>Transforming Research Through eSource & Standards This CDER project is developing and testing an implementation approach which employs multiple standards synergistically to enable the use of EHRs for eSource data collection. The work aims to highlight increased efficiencies in many points of the end-to-end work flow of clinical healthcare and research.</p>	<p>Q1: In FY18 Q1, the project continued system development, specifying the data elements to be incorporated an EHR-to-EDC system for pilot testing, and working through the complexities of their EHR system Applied Program Interfaces (APIs) to allow bi-directional system communication. Q2: No updates this quarter Q3: No updates this quarter</p>	Req Definition	Alt Analysis*	Development	Testing	Adoption	Implementation	Policy

Goal 2: Improve the postmarket risk management strategies and pharmacovigilance & surveillance of medical products by using data standards

Projects for Goal 2 address standards identification and use in FDA’s mission to protect public health through medical product safety and postmarketing surveillance. Projects that highlight the communication of essential risk evaluation and mitigation strategies, and standards for electronic transmission of individual case safety reports with external stakeholders are highlighted here.

Table 2. Postmarket Projects

Project Title and Description	Project Update	Project Stage						
<p>E2B IND Safety Report This CDER and CBER pilot project is testing the receipt and processing of Investigational New Drug (IND) safety reports submission using E2B standards.</p>	<p>Q1: In FY18 Q1, conducted pilot test which included receiving and processing IND Safety Reports in E2B format. Began drafting new review process and analytical tool requirements. Q2: No updates this quarter Q3: No updates this quarter</p>	Req Definition	Alt Analysis	Development*	Testing	Adoption	Implementation	Policy
<p>Development of ICSR E2B(R3) Validator for Industry Use for Submission of Vaccine Adverse Events This CBER Project will provide a freely available validator, in the eVAERS Pre-Production environment, that submitters can use to check individual case safety report (ICSR) submissions for FDA Regional Conformance to the FDA ICH E2B(R3) format for Vaccine ICSRs prior to officially submitting them to CBER.</p>	<p>Work will begin FY18 Q4 to develop the eVAERS Pre-Production environment to enable submitters to check ICSR submissions prior to officially submitting them to CBER.</p>	Req Definition	Alt Analysis	Development*	Testing	Adoption	Implementation	Policy

Project Title and Description	Project Update	Project Stage						
<p>Integrating REMS Information into SPL</p> <p>The objective of this CDER project is to capture and submit structured information about Risk Evaluation and Mitigation Strategies (REMS) and official FDA-approved REMS Documents in Structured Product Labeling (SPL).</p>	<p>In FY18 Q1, the project published draft guidance (FDA-2017-E-4282) under 745A(a) on September 5, 2017 to move towards requiring REMS submissions in SPL format. Comments on guidance are under review. CDER plans to finalize the guidance by FY19 Q1, paving the way for a requirement to take effect in 2020.</p> <p>Q2: No updates this quarter</p> <p>Q3: No updates this quarter</p>	Req Definition	Alt Analysis	Development	Testing	Adoption	Implementation	Policy*
<p>Grant Projects for Therapeutic Areas & Animal Efficacy and Natural History Studies</p> <p>This CDER project provides program and subject matter expertise to awarded grant projects.</p>	<p>The following Clinical TA grants are in progress:</p> <ul style="list-style-type: none"> • Clinical Data Interchange Standards Consortium (CDISC) Therapeutic Area User Guide (TAUG) for Lung Cancer is in the development stage • CDISC TAUG for Clostridium Difficile Associated Diarrhea was progressing through the CDISC review process at end of FY18 Q3 • CDISC TAUG for Treatment of HIV was progressing through the CDISC process review at end of FY18 Q3 <p>The CDISC Improved Data Standards for Animal Efficacy Studies and Natural History Studies for Animal Rule project is in the development stage. The project is planning to publish a Standard for Exchange of Nonclinical Data Implementation Guide: Animal Rule (SENDIG-AR).</p> <p>To see the list of the grant projects underway, see CDER's Grant Program for Data Standards Development webpage.</p>	Req Definition	Alt Analysis	Development*	Testing	Adoption	Implementation	Policy

Goal 3: Implement common data standards to improve the quality and integrity of marketed medical products

Projects for Goal 3 address medical product quality and identification of contamination and other production failures with common data standards. Projects that highlight the development and implementation of data standards that describe manufacturing and testing of medical products, International Standards Organization (ISO) standards implementation, and complete essential facility and manufacturing information through submission requirements are highlighted here.

Table 3. Quality Projects

Project Title and Description	Project Update	Project Stage						
<p>Pharmaceutical Quality/ Chemistry, Manufacturing, and Controls Data Standardization</p> <p>This CBER-CDER project will identify and standardize data elements, terminologies, and data structures to enable automation of key analyses of Pharmaceutical Quality (PQ)/ Chemistry, Manufacturing, and Controls (CMC) data to support more efficient and effective regulatory decision-making.</p>	<p>Q1: The project continues the review of comments received to the Draft Standardization of PQ/CMC Data Elements and Terminologies (FDA-2017-N-2166). Began evaluating Identification of Medicinal Product (IDMP) standards for alignment with PQ/CMC draft data elements and terminologies.</p> <p>Q2: No updates this quarter</p> <p>Q3: The project is performing analysis on different data exchange formats, and preparing for the Standardized Data for PQ/CMC Public Meeting on October 19, 2018. Completed the review of all FRN comments and evaluation of IDMP standards for alignment with PQ/CMC data elements.</p>	Req Definition	Alt Analysis	Development*	Testing	Adoption	Implementation	Policy

Project Title and Description	Project Update	Project Stage						
<p>IDMP Project</p> <p>This project has multiple use cases focused on the adoption of ISO Identification of Medicinal Product (IDMP) standards: 1. Medicinal Product ID (MPID) , 2. Substance ID (SubID), 3. Pharmaceutical Product ID (PhPID), 4. Route of Administration, Dosage Form, and 5. Units of Measure).</p> <p>These ISO standards define medicinal product information for regional and global data sharing. Generally, the use cases focus on safety (e.g., ICSRs) and can support quality (e.g., PQ / CMC).</p>	<p>Established IDMP work streams and working groups for each of the five ISO standards.</p> <ul style="list-style-type: none"> Confirmed that MPID is defined regionally by FDA’s ISO 11615 compatible National Drug Code (NDC). The first two segments of the NDC (i.e., labeler code and product code) are ISO 11615 compatible with the MPID specification. Global Substance Registration System (GSRS) v2.2 is in production and uses the ISO compatible Unique Ingredient Identifier (UNII) and ISO compatible Unified Codes for Units of Measure (UCUM) for SubID and units of measure, respectively. NCI/EVS and FDA have mapped FDA Controlled Terminology for SPL to EDQM. 	Req Definition	Alt Analysis	Development	Testing	Adoption	Implementation ¹	Policy
<p>Post Approval Changes Rulemaking & Submission Standards</p> <p>This CBER-CDER project is focused on improving submission requirements to ensure that essential facility location, production information, and an up-to-date view of the CMC process are captured completely, and in a format that is conducive to electronic receipt, storage and usage.</p>	<p>Q2: The project continues to assess and refine the proposed changes that are undergoing internal agency review.</p> <p>Q3: No updates this quarter</p>	Req Definition	Alt Analysis	Development*	Testing	Adoption	Implementation	Policy

¹ As reported in the [Action Plan v2.7](#), IDMP (ISO 11238) was implemented as part of the GSRS and CDER implemented the Product Master Data domain that is referenced by other CDER applications, as appropriate.

Goal 4: Promote innovation in the development and use of data standards

Projects for Goal 4 address research and development in pursuit of innovation to keep pace with advances in medical science and regulatory review. Projects that highlight implementation of new data standards, encourage the use of electronic health records to support clinical trials, and evaluation of the feasibility of representing real world data in an electronic standardized format are highlighted here.

Table 4. Innovation Projects

Project Title and Description	Project Update	Project Stage						
<p>Clinical Outcomes Assessment This CDER project is focused on the development and evaluation of clinical outcome assessments (COA) submitted in support of regulatory submissions.</p>	<p>The following Questionnaires, Ratings, and Scales are currently under review by FDA:</p> <ul style="list-style-type: none"> • Ten Meter Walk • 4 Stair Ascend • 4 Stair Descend • Rise from Floor <p>FDA submitted comments to the following:</p> <ul style="list-style-type: none"> • Clinical Global Impression 	Req Definition*	Alt Analysis	Development	Testing	Adoption	Implementation	Policy
<p>Patient-Centered Outcomes Research Trust Fund (PCORTF) Common Data Harmonization Pilot Project This CDER project is focused on the development of a proof of concept solution to enable a researcher to make a single query usable across four distinct Common Data Model formats from FDA's Sentinel Program, the Observational Health Data Sciences and Informatics program, the National Patient-Centered Clinical Research Network, and the Accrual of Patients to Clinical Trials network. FDA is coordinating with its partners, the National Cancer Institute, National Library of Medicine, National Center for Advancing Translational Sciences, and the Office of the National Coordinator for Health Information Technology.</p>	<p>In FY18 Q3, architectural development, data mapping activities, and planning with partners who will test this pilot concept continued.</p>	Req Definition	Alt Analysis*	Development	Testing	Adoption	Implementation	Policy

Goal 5: Ensure effective communication and collaboration with stakeholders on data standards.

Program operations for Goal 5 execute CBER and CDER’s communication and collaboration with internal and external stakeholders for the successful development, implementation, and use of data standards to support regulatory review of medical products. Document updates that report progress towards meeting FDA goals are highlighted here.

Table 5. Communication Efforts

Program Operations	Updates
Webpage Updates	The following webpages were updated with the eCTD submission types and sub-types, technical rejection criteria, conformance guide, and action plan documents referenced below: <ul style="list-style-type: none"> • Study Data Standards Resources • Study Data for Submissions to CDER and CBER • CDER Data Standards Program • Electronic Common Technical Document (eCTD)
Federal Register Notices (FRNs)	Technical Specifications for Electronic Submissions Establishment of a Public Docket (FDA-2018-D-1216-0002) – June 18, 2018
eCTD Submission Standards	In April, the following document was published: <ul style="list-style-type: none"> • Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications In May, the following document was updated: <ul style="list-style-type: none"> • Technical Rejection Criteria for Study Data In June, the following document was updated: <ul style="list-style-type: none"> • eCTD Validation Criteria
Technical Specifications and Conformance Guide Updates	FDA has and will continue to provide (as needed) technical specifications documents to aid in the submission of standardized data.
Action Plan	The Data Standards Action Plan v3.1 was published on May 21, 2018.

Program Operations	Updates
<p>Outreach Opportunities, Public Meetings & Educational Activities'</p>	<ul style="list-style-type: none"> • FDA Webinars <ul style="list-style-type: none"> ○ Webinars are planned to focus on various data standards topics. • Public Meetings <ul style="list-style-type: none"> ○ PDUFA VI, Electronic Submissions and Data Standards, March 21, 2018 (postponed due to government closure); was rescheduled for July 10, 2018.

Goal 6: Improve the management and usability of the volume of information through data standards

As outlined in the [Data Standards Strategy](#) document, technology is critically important and serves as an enabler for reviewers to access and use large amounts of data and information that is received and generated. Several data standards development projects are already underway, as highlighted earlier in this document, to promote access to high-quality, standardized data including the PQ/CMC Standardization and IDMP projects. CDER also continues to define and enhance ways to better capture information created internally to support continued knowledge management activities. Progress towards the Goal 6 objectives will be highlighted annually in the Data Standards Program Annual Assessment and not tracked quarterly.

4 Upcoming Work

This section will highlight upcoming work related to one or more Data Standards Strategy goals that have not been fully initiated and are currently not a full, defined project in progress. It is a best effort to align with Agency announcements and informing on these efforts. FY18 Q3 highlights include: FDA is continuing to collaborate with the European Medicines Agency at HL7 on developing FHIR resources.

Appendix A. Project Stage and Description

The Stage Name column lists the stage name as outlined in **Figure 2** and a shortened name listed in the tables above. The rows highlighted in yellow* are processes owned by SDOs, other rows are FDA owned processes. As discussed in the next section, there is variation in all data standards projects so not all processes are needed for every project.


Table 6. Standard Development Project Stages

Stage Name	Stage Description
Define Scope and Requirement (Req Definition)	<p>A plan is developed that can include a description of the data standard need, impact on tools, processes, and information technology infrastructure, high-level concept of operations, future state benefits, and high level requirements.</p> <p>For study data-related projects, FDA subject matter experts and document resources (e.g., case report forms, guidance documents) are used to develop requirements for study data standards development.</p>
Analyze Alternatives (Alt Analysis)	<p>If needed, FDA can conduct alternative analyses to assess options and recommendations for addressing the data standards need defined in the business case. Stakeholder input is a critical part of this effort and could include a request for public comment or input in addition to planned communications (as outlined in the Communication Plan).</p>
Initiation*	<p>The SDO, grantee, or other lead group working with the FDA and other subject matter experts defines the project scope (e.g., what is needed for regulatory review decision making), develops a charter to define the project and ensure available resources, develops a plan, and conducts a kick off of the project.</p>
Development*	<p>The SDO, grantee, or other lead group conducts an iterative process of data element identification (e.g., elements need to describe the study primary endpoint), definition, validation, and conducts a review with defined expert groups. FDA’s subject matter experts participate throughout the development phase. A key output is an implementation guide for the study data standard.</p>
Internal Review*	<p>During this stage, the lead group conducts an internal review to ensure readiness for the public review period.</p>
Public Review*	<p>The lead group facilitates a public review comment period. Comments are addressed per the lead group’s process.</p>
Public Release*	<p>An initial release of the study data standard is released for public use.</p>

Stage Name	Stage Description
Test Standards (Testing)	<p>A project may be required to test that all identified factors are assessed (e.g., scale, impact, suitability for FDA regulatory review needs, compatibility with FDA infrastructure) and that all policy, regulatory, guidance, and technical specification needs are identified.</p> <p>For study data, FDA may use converted or sample data sets to test the study data standard to simulate regulatory review decision making. Having the business rules and/or conformance checks available for a new or updated standard at time of SDO release will be important to FDA's testing efforts.</p>
Determine Data Standard Adoption (Adoption)	<p>If needed, policy, regulatory, guidance, and technical specification needs identified for a given data standards change are addressed to support implementation.</p>
Implement Standard (Implementation)	<p>The data standard change is being implemented into the FDA environment. This phase includes all the steps to make this part of the regulatory review process. Implementation is considered complete when data can be successfully processed, reviewed, and archived utilizing the new standard.</p>
FRN/Guidance	<p>FDA will issue a FRN (and guidance as needed) if the use of a new standard is required.</p>

The data standards development stages described above are shown graphically in **Figure 2**.

Figure 2. Data Standards Development Framework



Appendix B: Project to Goals/Objectives Mapping

The following table maps the projects listed in the tables above to the objectives outlined for each goal in the CBER-CDER Data Standards Strategy. Some projects may align to more than one goal and objective.

Table 7. Project Mapping

Projects	Goal 1				Goal 2		Goal 3			Goal 4			
	1.1	1.2	1.3	1.4	2.1	2.2	3.1	3.2	3.3	4.1	4.2	4.3	4.4
Evaluation and Testing of the SEND standard for CBER	x												
Study Data Standards Testing	x												
BRIDG Architecture Review	x												
eCTD v4.0 Project	x												
Source Data Capture from EHRs: Using Standardized Clinical Research Data				x								x	
Transforming Research Through eSource and Standards				x								x	
E2B IND Safety Report	x												
Development of ICSR E2B(R3) Validator for Industry Use for Submission of Vaccine Adverse Events						x							
Integrating REMS Information into SPL					x								
Develop Electronic Establishment Registration and Product Listing System									x				
Grant Projects for Therapeutic Areas & Animal Efficacy and Natural History Studies	x												
Pharmaceutical Quality (PQ)/, Chemistry, Manufacturing, and Controls (CMC) Data Standardization							x						
IDMP Project						x		x					
Annual Report Rulemaking & Submission Standards									x				
Clinical Outcomes Assessment	x	x									x		
PCORTF Common Data Harmonization Pilot Project													x

Appendix C: Glossary of Acronyms

API	Applied Program Interfaces
BR&R	HL7 Biomedical Research and Regulation Group
BRIDG	Biomedical Research Integrated Domain Group
CBER	Center for Biologics Evaluation and Research
CDER	Center for Drug Evaluation and Research
CDISC	Clinical Data Interchange Standards Consortium
COA	Clinical Outcomes Assessment
DF	Dosage Form
eCTD	Electronic Common Technical Document
EDC	Electronic Data Capture
EDQM	European Directorate for Quality Medicines
EHR	Electronic Health Record
FHIR	Fast Healthcare Interoperability Resources
FRN	Federal Register Notices
FY	Fiscal Year
GSRs	Global Substance Registration System
HCT/P	Human Cells, Tissues and Cellular and Tissue-Based Products
HL7	Health Level Seven
ICH	International Council for Harmonisation
ICSR	Individual Case Safety Report
IDMP	Identification of Medicinal Product
IND	Investigational New Drug
ISO	International Organization for Standardization
MPID	Medicinal Product Identifier
NDC	National Drug Codes
PCORTF	Patient-Centered Outcomes Research Trust Fund
PDUFA	Prescription Drug User Fee Act
PhPID	Pharmaceutical Product Identifier
PQ/CMC	Pharmaceutical Quality/ Chemistry, Manufacturing, and Controls
REMS	Risk Evaluation and Mitigation Strategies
RoA	Route of Administration
SDO	Standards Development Organization
SEND	Standard for Exchange of Nonclinical Data
SENDIG-AR	Standard for Exchange of Nonclinical Data Implementation Guide: Animal Rule
SME	Subject Matter Expert
SPL	Structured Product Labeling
TA	Therapeutic Area
TAUG	CDISC Therapeutic Area User Guide
UNII	Unique Ingredient Identifier
UoM	Units of Measure